Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder. The company is also developing AXS-07, which is in Phase III clinical trial for the treatment of migraine; AXS-12 that is in Phase II clinical trial for the treatment of in narcolepsy; AXS-09, which has completed Phase I clinical trial for the treatment of various CNS disorders; and AXS-02, which is in Phase III clinical trial for the treatment of the pain of knee osteoarthritis associated with bone marrow lesions, and for the treatment of chronic low back pain associated with Modic changes. In addition, it is developing AXS-06 that has completed Phase I clinical trial for the treatment of osteoarthritis and rheumatoid arthritis and for the reduction of the risk of nonsteroidal anti-inflammatory drug associated gastrointestinal ulcers. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase II trial in smoking cessation. The company was founded in 2012 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone212-332-3241
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees29
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Axsome Therapeutics (NASDAQ:AXSM) Frequently Asked Questions
What is Axsome Therapeutics' stock symbol?
Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."
How were Axsome Therapeutics' earnings last quarter?
Axsome Therapeutics Inc (NASDAQ:AXSM) announced its earnings results on Thursday, May, 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.01. View Axsome Therapeutics' Earnings History.
When is Axsome Therapeutics' next earnings date?
What price target have analysts set for AXSM?
6 brokers have issued 1 year price targets for Axsome Therapeutics' shares. Their forecasts range from $25.00 to $45.00. On average, they anticipate Axsome Therapeutics' stock price to reach $29.1667 in the next twelve months. This suggests a possible upside of 17.9% from the stock's current price. View Analyst Price Targets for Axsome Therapeutics.
What is the consensus analysts' recommendation for Axsome Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Axsome Therapeutics.
What are Wall Street analysts saying about Axsome Therapeutics stock?
Here are some recent quotes from research analysts about Axsome Therapeutics stock:
- 1. According to Zacks Investment Research, "Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York. " (5/22/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $25 PT on AXSM. Axsome pursues new indications for drugs approved in other indications, sometimes using new combinations or new routes of administration. We see this as a relatively balanced risk strategy and view the pipeline as robust, with trials spanning CNS and pain indications. We particularly value AXS-05 and its applicability to neuropsychiatric indications where we feel the individual compounds dextromethorphan (DM) and bupropion (BP) are derisked through proven efficacy in related indications." (3/21/2019)
Has Axsome Therapeutics been receiving favorable news coverage?
News stories about AXSM stock have been trending somewhat negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Axsome Therapeutics earned a coverage optimism score of -1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Axsome Therapeutics' key competitors?
Some companies that are related to Axsome Therapeutics include Ultragenyx Pharmaceutical (RARE), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), Mirati Therapeutics (MRTX), Biohaven Pharmaceutical (BHVN), Arena Pharmaceuticals (ARNA), Reata Pharmaceuticals (RETA), Intercept Pharmaceuticals (ICPT), The Medicines (MDCO), Amneal Pharmaceuticals (AMRX), Uniqure (QURE), PTC Therapeutics (PTCT), Myokardia (MYOK) and Arrowhead Pharmaceuticals (ARWR).
What other stocks do shareholders of Axsome Therapeutics own?
Who are Axsome Therapeutics' key executives?
Axsome Therapeutics' management team includes the folowing people:
- Dr. Herriot Tabuteau M.D., Founder, Chairman, CEO & Pres (Age 51)
- Mr. Nick Pizzie, CFO & Principal Accounting Officer (Age 44)
- Mr. Mark Jacobson, Sr. VP of Operations & Sec. (Age 36)
- Dr. Cedric O'Gorman M.D., MBA, Sr. VP of Clinical Devel. & Medical Affairs (Age 44)
- Joseph Debrah-Afful, Director of Fin.
When did Axsome Therapeutics IPO?
(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.
Who are Axsome Therapeutics' major shareholders?
Axsome Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Alethea Capital Management LLC (3.42%), BlackRock Inc. (1.40%), Laurion Capital Management LP (0.66%), Royce & Associates LP (0.55%), Schonfeld Strategic Advisors LLC (0.37%) and Parametric Portfolio Associates LLC (0.28%). Company insiders that own Axsome Therapeutics stock include Mark Coleman, Mark E Saad and Nick Pizzie. View Institutional Ownership Trends for Axsome Therapeutics.
Which institutional investors are selling Axsome Therapeutics stock?
Which institutional investors are buying Axsome Therapeutics stock?
AXSM stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Alethea Capital Management LLC, Laurion Capital Management LP, Schonfeld Strategic Advisors LLC, Parametric Portfolio Associates LLC, EAM Global Investors LLC, Morgan Stanley and ExodusPoint Capital Management LP. Company insiders that have bought Axsome Therapeutics stock in the last two years include Mark Coleman, Mark E Saad and Nick Pizzie. View Insider Buying and Selling for Axsome Therapeutics.
How do I buy shares of Axsome Therapeutics?
Shares of AXSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Axsome Therapeutics' stock price today?
One share of AXSM stock can currently be purchased for approximately $24.73.
How big of a company is Axsome Therapeutics?
Axsome Therapeutics has a market capitalization of $823.63 million. The company earns $-30,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Axsome Therapeutics employs 29 workers across the globe.
What is Axsome Therapeutics' official website?
How can I contact Axsome Therapeutics?
Axsome Therapeutics' mailing address is 25 BROADWAY 9TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-332-3241.
MarketBeat Community Rating for Axsome Therapeutics (NASDAQ AXSM)
MarketBeat's community ratings are surveys of what our community members think about Axsome Therapeutics and other stocks. Vote "Outperform" if you believe AXSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
